Omeros (NASDAQ:OMER) Trading Up 6.9% – Time to Buy?

Shares of Omeros Co. (NASDAQ:OMER) were up 6.9% during trading on Thursday . The company traded as high as $9.76 and last traded at $9.89. Approximately 149,168 shares were traded during mid-day trading, a decline of 69% from the average daily volume of 488,698 shares. The stock had previously closed at $9.25.

Wall Street Analyst Weigh In

A number of analysts have recently commented on OMER shares. StockNews.com raised Omeros from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. RODMAN&RENSHAW raised Omeros to a “strong-buy” rating in a research note on Thursday, November 14th. D. Boral Capital reissued a “buy” rating and set a $36.00 target price on shares of Omeros in a research note on Thursday. Rodman & Renshaw began coverage on Omeros in a research note on Thursday, November 14th. They set a “buy” rating and a $9.00 target price for the company. Finally, Cantor Fitzgerald reissued a “neutral” rating on shares of Omeros in a research note on Thursday, November 14th. Three equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Omeros has a consensus rating of “Moderate Buy” and an average target price of $22.50.

Omeros Trading Down 4.5 %

The business has a 50 day moving average of $9.27 and a 200-day moving average of $6.71. The firm has a market capitalization of $531.98 million, a P/E ratio of -3.97 and a beta of 1.98.

Hedge Funds Weigh In On Omeros

A number of large investors have recently bought and sold shares of the company. Two Sigma Investments LP boosted its position in Omeros by 8.8% during the 4th quarter. Two Sigma Investments LP now owns 162,991 shares of the biopharmaceutical company’s stock worth $1,610,000 after acquiring an additional 13,201 shares during the last quarter. ProShare Advisors LLC boosted its position in Omeros by 75.0% during the 4th quarter. ProShare Advisors LLC now owns 18,496 shares of the biopharmaceutical company’s stock worth $183,000 after acquiring an additional 7,927 shares during the last quarter. Nomura Holdings Inc. boosted its position in Omeros by 136.2% during the 4th quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company’s stock worth $7,383,000 after acquiring an additional 430,932 shares during the last quarter. Millennium Management LLC boosted its position in Omeros by 46.2% during the 4th quarter. Millennium Management LLC now owns 85,671 shares of the biopharmaceutical company’s stock worth $846,000 after acquiring an additional 27,088 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Omeros by 3.6% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,831 shares of the biopharmaceutical company’s stock worth $314,000 after acquiring an additional 1,110 shares during the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.